228 related articles for article (PubMed ID: 22718841)
1. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis.
Jiang T; Zhuang J; Duan H; Luo Y; Zeng Q; Fan K; Yan H; Lu D; Ye Z; Hao J; Feng J; Yang D; Yan X
Blood; 2012 Sep; 120(11):2330-9. PubMed ID: 22718841
[TBL] [Abstract][Full Text] [Related]
2. Impaired tumor angiogenesis and VEGF-induced pathway in endothelial CD146 knockout mice.
Zeng Q; Wu Z; Duan H; Jiang X; Tu T; Lu D; Luo Y; Wang P; Song L; Feng J; Yang D; Yan X
Protein Cell; 2014 Jun; 5(6):445-56. PubMed ID: 24756564
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of CD146 lessens uveal melanoma progression through reducing angiogenesis and vasculogenic mimicry.
Zhang R; Chen X; Chen S; Tang J; Chen F; Lin Y; Reinach PS; Yan X; Tu L; Duan H; Qu J; Hou Q
Cell Oncol (Dordr); 2022 Aug; 45(4):557-572. PubMed ID: 35716258
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA 329 suppresses angiogenesis by targeting CD146.
Wang P; Luo Y; Duan H; Xing S; Zhang J; Lu D; Feng J; Yang D; Song L; Yan X
Mol Cell Biol; 2013 Sep; 33(18):3689-99. PubMed ID: 23878390
[TBL] [Abstract][Full Text] [Related]
5. CD146 mediates VEGF-induced melanoma cell extravasation through FAK activation.
Jouve N; Bachelier R; Despoix N; Blin MG; Matinzadeh MK; Poitevin S; Aurrand-Lions M; Fallague K; Bardin N; Blot-Chabaud M; Vely F; Dignat-George F; Leroyer AS
Int J Cancer; 2015 Jul; 137(1):50-60. PubMed ID: 25449773
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
7. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
[TBL] [Abstract][Full Text] [Related]
8. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth.
Yan X; Lin Y; Yang D; Shen Y; Yuan M; Zhang Z; Li P; Xia H; Li L; Luo D; Liu Q; Mann K; Bader BL
Blood; 2003 Jul; 102(1):184-91. PubMed ID: 12609848
[TBL] [Abstract][Full Text] [Related]
9. Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway.
Tang N; Shi L; Yu Z; Dong P; Wang C; Huo X; Zhang B; Huang S; Deng S; Liu K; Ma T; Wang X; Wu L; Ma XC
Oncotarget; 2016 Jan; 7(3):3533-47. PubMed ID: 26657289
[TBL] [Abstract][Full Text] [Related]
10. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
11. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-kappaB activation.
Bu P; Gao L; Zhuang J; Feng J; Yang D; Yan X
Mol Cancer Ther; 2006 Nov; 5(11):2872-8. PubMed ID: 17121934
[TBL] [Abstract][Full Text] [Related]
13. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
[TBL] [Abstract][Full Text] [Related]
14. VEGF/Flk1 Mechanism is Involved in Roxarsone Promotion of Rat Endothelial Cell Growth and B16F10 Xenograft Tumor Angiogenesis.
Chen S; Xu J; Wei Q; Zhao Z; Chen X; Cui H; Zhang Y
Sci Rep; 2019 Nov; 9(1):17417. PubMed ID: 31758020
[TBL] [Abstract][Full Text] [Related]
15. Glycation of vitronectin inhibits VEGF-induced angiogenesis by uncoupling VEGF receptor-2-αvβ3 integrin cross-talk.
Wang L; Zhang X; Pang N; Xiao L; Li Y; Chen N; Ren M; Deng X; Wu J
Cell Death Dis; 2015 Jun; 6(6):e1796. PubMed ID: 26111058
[TBL] [Abstract][Full Text] [Related]
16. EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF.
Khayati F; Pérez-Cano L; Maouche K; Sadoux A; Boutalbi Z; Podgorniak MP; Maskos U; Setterblad N; Janin A; Calvo F; Lebbé C; Menashi S; Fernandez-Recio J; Mourah S
Oncotarget; 2015; 6(12):9766-80. PubMed ID: 25825981
[TBL] [Abstract][Full Text] [Related]
17. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
18. Endothelial CD146 is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization.
Zheng C; Qiu Y; Zeng Q; Zhang Y; Lu D; Yang D; Feng J; Yan X
Int J Biochem Cell Biol; 2009 Nov; 41(11):2163-72. PubMed ID: 19782948
[TBL] [Abstract][Full Text] [Related]
19. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
[TBL] [Abstract][Full Text] [Related]
20. A cyclic peptide reproducing the α1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth.
Assareh E; Mehrnejad F; Mansouri K; Esmaeili Rastaghi AR; Naderi-Manesh H; Asghari SM
Biochem J; 2019 Feb; 476(4):645-663. PubMed ID: 30700502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
